Mov Disord Vol 31, Suppl 2 Archives - Page 127 of 207 - MDS Abstracts

2016 International Congress
Modeling dementia with Lewy bodies using patient-derived neurons
D.H. Adamowicz, J. Mertens, D.P. Salmon, D.R. Galasko, S. Roy, F.H. Gage (La Jolla, CA, USA)
Objective: To model Dementia with Lewy bodies (DLB) using neurons derived from patients clinically diagnosed with the disease. Background: A major challenge in neurodegenerative disease…
2016 International Congress
Catechol-o-methyltransferase Val158Met polymorphism influences prefrontal executive function in early Parkinson’s disease
Y. Zhang, Y. Zhang, K. Nie, S. Feng, L. Wang, J. Zhao, Z. Huang, L. Wang (Guangzhou, People's Republic of China)
Objective: The Catechol-O-Methyltransferase (COMT) Val158Met polymorphism has been proposed to be associated with increased risk of PD and have a specific impact on dopamine-mediated prefrontal…
2016 International Congress
Genetic factors influencing frontostriatal dysfunction and the development of dementia in Parkinson’s disease
I. Huertas Fernandez, S. Jesus, F.J. Garcia Gomez, J.A. Lojo, I. Bernal Bernal, M. Bonilla Toribio, J.F. Martin Rodriguez, D. Garcia Solis, P. Gomez Garre, P. Mir (Sevilla, Spain)
Objective: To investigate the role of APOE, MAPT, COMT, SNCA and GBA genes in both striatal dopaminergic denervation and the development of dementia in Parkinson's…
2016 International Congress
Occurrence and pattern of cognitive deficits in prodromal Parkinson’s disease
C. Pausch, J. Spiegel, F.A. Wollenweber, C. Bayer, U. Dillmann, K. Fassbender, S. Behnke (Homburg Saar, Germany)
Objective: To assess a possible cognitive impairment and its specific profile in the prodromal phase of Parkinson's disease (PD). Background: Cognitive impairment is common in…
2016 International Congress
Monoaminergic biomarkers of cognitive decline in Parkinson’s disease and Lewy body dementia
S. van der Zee, Y. Vermeiren, T. Aerts, D. van Dam, M.J. Gerritsen, J.M. Spikman, T. van Laar, P.P. de Deyn (Groningen, Netherlands)
Objective: The objective of this study was the identification of biochemical markers of cognitive impairment in Parkinson's disease (PD) and dementia with Lewy bodies (DLB)…
2016 International Congress
Impulsive action tendencies in GPi DBS Parkinson’s patients
D. Martinez-Ramirez, C.S. Little, J.P. Chapman, S. Carbunaru, J.C. Giugni, M.W. Vasquez, F. Chai, R. Walz, A. Sririam, K. Kanoff, S.A. Wylie, M.S. Okun (Gainesville, FL, USA)
Objective: To test the effects of GPi DBS on susceptibility to impulsive action errors and the proficiency of reactive inhibitory control to counteract interference from…
2016 International Congress
The alterations in behavioral memory for prolongation disease duration in patients with Parkinson’s disease
M. Saruwatari, Y. Kobayashi, A. Kumon, K. Hasegawa (Sagamihara, Japan)
Objective: Aim of this study is to assess the alterations in daily behavioral memory for prolongation of disease duration in PD. Background: We are continuing…
2016 International Congress
Neuropsychological correlates of impulse control disorders and punding in Parkinson´ s disease
G. Santangelo, F. Falco, M. Vicidomini, R. Allocca, P. Barone, C. Vitale (Caserta, Italy)
Objective: To investigate the relationship between cognitive deficits, Impulse Control Disorders (ICDs) and Punding in Parkinson's disease (PD). Background: The neuropsychological correlates of ICDs and…
2016 International Congress
Prevalence of depression in Parkinson’s disease patients
A.M. Weldehana (Addis Ababa, Ethiopia)
Objective: The objective of this study was to determine the prevalence of depression in PD patients taking into account the different settings and different diagnostic…
2016 International Congress
Ambulatory assessment of tremor
M. Horne, S. O'Connor, P. Churchward, T. Perera, M. Braybrook (Parkville, Australia)
Objective: To develop ambulatory assessment of tremor in Parkinson's disease (PD) throughout the day, in relationship to treatment and fluctuations in bradykinesia. Background: PD is…